Thu. 14 Mar 2024, 2:38am ET
Benzinga
News
- ZL-1310 is an innovative ADC targeting DLL3, a promising therapeutic target in small cell lung cancer and other DLL3+ solid tumors
- Data will be shared in a poster presentation at the European Lung Cancer Congress 2024 (ELCC 2024)